BCL9L and colonic neoplasm: Sun et al. find that miR-22 is downregulated in colon cancer, overexpression of miR-22 significantly inhibits cell proliferation, migration, metastasis, and epithelial-mesenchymal (EMT) transition by directly targeting BCL9L [46].